Table 2

Overall relationship between active disease (DAS>2.4) after 3 months of induction DMARD therapy and response to GCs at 2 weeks (A) and also stratified for induction therapy arms (B)

Active disease
Yes (n=42)No (n=78)
A.
 Response to GCs at 2 weeks
  Good, no (%)6 (13)39 (87)
  Moderate, no (%)17 (39)27 (61)
  None, no (%)19 (61)12 (39)
B.
 GCs response at 2 weeks
  A. MTX+SSZ+HCQ+GCs IM, no (%)
   Good3 (17)15 (83)
   Moderate3 (21)11 (79)
   None5 (45)6 (55)
  B. MTX+SSZ+HCQ+GCs oral, no (%)
   Good1 (6)16 (94)
   Moderate5 (42)7 (58)
   None4 (40)6 (60)
  C. MTX+GCs oral, no (%)
   Good2 (20)8 (80)
   Moderate9 (50)9 (50)
   None10 (100)0 (0)
  • DAS, Disease Activity Score; DMARDs, disease-modifying antirheumatic drugs; GCs, glucocorticoids; HCQ, hydroxychloroquine; IM, intramuscular; MTX, methotrexate, SSZ, sulfasalazine.